Reuters logo
BRIEF-BioCryst Pharmaceuticals reports Q3 loss per share of $0.18
2017年11月7日 / 中午12点19分 / 17 天前

BRIEF-BioCryst Pharmaceuticals reports Q3 loss per share of $0.18

Nov 7 (Reuters) - BioCryst Pharmaceuticals Inc:

* Reports third quarter 2017 financial results

* Q3 loss per share $0.18

* Q3 revenue $8.8 million versus $7.8 million

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

* Q3 revenue view $4.6 million -- Thomson Reuters I/B/E/S

* Expect to start single required phase 3 efficacy and long-term safety trials for BCX7353 in Q1 2018 ​

* ‍U.S. Orphan Drug Designation for BCX7353 received from FDA​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below